Atosiban SUN 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0021 
The marketing authorisation holder took the 
02/02/2022 
Labelling and 
The marketing authorisation holder took the opportunity to 
opportunity to align the PI to the latest QRD 
PL 
align the PI to the latest QRD template (version 10.2). 
template (version 10.2). 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IA/0020/G 
This was an application for a group of variations. 
10/12/2021 
n/a 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
N/0019 
Minor change in labelling or package leaflet not 
20/10/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0017 
B.II.z - Quality change - Finished product - Other 
08/04/2020 
n/a 
variation 
N/0018 
Minor change in labelling or package leaflet not 
31/03/2020 
connected with the SPC (Art. 61.3 Notification) 
N/0016 
Minor change in labelling or package leaflet not 
30/08/2019 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
IA/0015 
B.II.e.3.b - Change in test procedure for the 
30/08/2019 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
N/0014 
Minor change in labelling or package leaflet not 
16/08/2018 
Labelling and 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
connected with the SPC (Art. 61.3 Notification) 
N/0013 
Minor change in labelling or package leaflet not 
24/07/2018 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
R/0012 
Renewal of the marketing authorisation. 
22/03/2018 
28/05/2018 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Atosiban SUN in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IAIN/0011 
B.II.b.1.a - Replacement or addition of a 
10/08/2017 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
N/0010 
Update of the package leaflet with revised contact 
25/08/2016 
28/05/2018 
PL 
details of the local representatives for Germany, 
Italy, Spain and the United Kingdom. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IA/0009 
A.4 - Administrative change - Change in the name 
22/01/2016 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IAIN/0008 
C.I.8.a - Introduction of or changes to a summary of 
28/09/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0007/G 
This was an application for a group of variations. 
26/06/2015 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0006 
B.II.d.1.g - Change in the specification parameters 
10/06/2015 
n/a 
and/or limits of the finished product - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter wit its 
corresponding test method as a result of a safety or 
quality issue 
IB/0005/G 
This was an application for a group of variations. 
18/02/2015 
n/a 
B.I.b.1.h - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
B.I.d.1.b.1 - Stability of AS - Change in the storage 
conditions - Change to more restrictive storage 
conditions of the AS 
B.I.a.4.f - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or replacement of an in-process test as a result of a 
safety or quality issue 
IA/0004 
B.II.d.2.a - Change in test procedure for the finished 
04/02/2015 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0003/G 
This was an application for a group of variations. 
13/10/2014 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IAIN/0002 
C.I.8.a - Introduction of or changes to a summary of 
21/11/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSMF location 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
24/10/2013 
15/10/2014 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 6/6 
 
 
 
 
 
 
 
 
 
